Viking Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Viking Therapeutics, Inc. reported a quarterly adjusted loss of $1.55​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -81 cents. The mean expectation of twenty analysts for the quarter was for a loss of $1.07 per share. Wall Street expected results to range from $-1.38 to -66 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Viking Therapeutics, Inc.'s reported EPS for the quarter was a loss of $1.55​.

• The company reported a quarterly loss of $183.19 million.

• Viking Therapeutics, Inc. shares had fallen by 23.7% this quarter and lost 29.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Viking Therapeutics, Inc. is $97.50, about 74.5% above its last closing price of $24.89

This summary was machine generated from LSEG data October 28 at 09:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)